AAPL342.56-6.65 (-1.90%) ▼|ABBV286.20+2.66 (+0.94%) ▲|ABT103.00-0.87 (-0.84%) ▼|ACN221.17+2.59 (+1.18%) ▲|ADBE217.71-3.97 (-1.79%) ▼|AMAT302.63-36.30 (-10.71%) ▼|AMD424.39-64.80 (-13.25%) ▼|AMGN435.64-0.66 (-0.15%) ▼|AMT184.21+3.06 (+1.69%) ▲|AMZN246.82-10.55 (-4.10%) ▼|AVGO304.41-42.24 (-12.19%) ▼|AXP301.70-9.41 (-3.02%) ▼|BA155.89-4.62 (-2.88%) ▼|BAC47.04-1.53 (-3.15%) ▼|BKNG144.91-2.41 (-1.64%) ▼|BLK1,101.72-34.09 (-3.00%) ▼|BMY58.80+0.46 (+0.79%) ▲|BNY141.24-3.59 (-2.48%) ▼|BRK-B570.00-2.04 (-0.36%) ▼|C110.62-4.66 (-4.04%) ▼|CAT510.45-26.92 (-5.01%) ▼|CL98.71+1.83 (+1.89%) ▲|CMCSA24.90+0.04 (+0.16%) ▲|COF178.66-3.10 (-1.71%) ▼|COP136.12+1.13 (+0.84%) ▲|COST1,102.15+8.32 (+0.76%) ▲|CRM180.62-2.69 (-1.47%) ▼|CSCO90.64-4.06 (-4.29%) ▼|CVS80.84+0.80 (+1.00%) ▲|CVX208.37+1.87 (+0.91%) ▲|DE609.25-15.64 (-2.50%) ▼|DHR220.36-7.20 (-3.16%) ▼|DIS117.98-2.27 (-1.89%) ▼|DUK129.78+0.92 (+0.71%) ▲|EMR150.93-6.67 (-4.23%) ▼|FDX303.99-10.65 (-3.38%) ▼|GD341.50-5.84 (-1.68%) ▼|GE309.62-9.26 (-2.90%) ▼|GEV699.33-56.95 (-7.53%) ▼|GILD166.43-0.10 (-0.06%) ▼|GM78.71-3.04 (-3.72%) ▼|GOOG264.00-7.02 (-2.59%) ▼|GOOGL265.29-7.37 (-2.70%) ▼|GS790.69-56.84 (-6.71%) ▼|HD339.04+2.36 (+0.70%) ▲|HON212.64-5.20 (-2.39%) ▼|IBM224.44+0.56 (+0.25%) ▲|INTC51.28-4.44 (-7.97%) ▼|INTU270.44-39.58 (-12.77%) ▼|ISRG399.05-8.19 (-2.01%) ▼|JNJ270.47+3.33 (+1.25%) ▲|JPM310.53-9.69 (-3.03%) ▼|KO96.99+0.90 (+0.94%) ▲|LIN502.83-7.38 (-1.45%) ▼|LLY1,347.11-4.01 (-0.30%) ▼|LMT565.50-6.35 (-1.11%) ▼|LOW220.84+1.70 (+0.78%) ▲|LRCX183.27-20.41 (-10.02%) ▼|MA625.59-0.91 (-0.15%) ▼|MCD273.24+0.89 (+0.33%) ▲|MDLZ66.28+0.59 (+0.90%) ▲|MDT99.94-0.67 (-0.67%) ▼|META560.84-35.38 (-5.93%) ▼|MMM177.99-0.48 (-0.27%) ▼|MO74.87+0.19 (+0.25%) ▲|MRK133.72+0.91 (+0.69%) ▲|MS165.67-9.31 (-5.32%) ▼|MSFT484.52-13.78 (-2.77%) ▼|MU594.51-95.93 (-13.89%) ▼|NEE83.45-0.34 (-0.41%) ▼|NFLX56.73-1.73 (-2.96%) ▼|NKE32.92-1.41 (-4.11%) ▼|NOW87.61-1.26 (-1.42%) ▼|NVDA125.53-20.45 (-14.01%) ▼|ORCL101.19-9.38 (-8.48%) ▼|PEP140.54+1.54 (+1.11%) ▲|PFE27.40-0.14 (-0.51%) ▼|PG169.37+1.52 (+0.91%) ▲|PLTR143.49-10.19 (-6.63%) ▼|PM184.09-2.34 (-1.26%) ▼|QCOM149.94-12.07 (-7.45%) ▼|RTX190.17-2.54 (-1.32%) ▼|SBUX103.13-1.34 (-1.28%) ▼|SCHW90.16-1.96 (-2.13%) ▼|SO93.13-0.16 (-0.17%) ▼|SPG224.35-0.87 (-0.39%) ▼|T22.31+0.46 (+2.11%) ▲|TMO669.54-19.21 (-2.79%) ▼|TMUS165.60+3.07 (+1.89%) ▲|TSLA345.82-28.59 (-7.64%) ▼|TXN263.75-22.00 (-7.70%) ▼|UBER63.47-2.13 (-3.25%) ▼|UNH339.85+9.37 (+2.84%) ▲|UNP287.29-3.34 (-1.15%) ▼|UPS106.22-2.89 (-2.65%) ▼|USB56.05-1.21 (-2.11%) ▼|V401.87-0.38 (-0.09%) ▼|VZ46.48+0.74 (+1.62%) ▲|WFC78.62-1.99 (-2.47%) ▼|WMT127.95+1.91 (+1.52%) ▲|XOM159.99+1.06 (+0.67%) ▲|AAPL342.56-6.65 (-1.90%) ▼|ABBV286.20+2.66 (+0.94%) ▲|ABT103.00-0.87 (-0.84%) ▼|ACN221.17+2.59 (+1.18%) ▲|ADBE217.71-3.97 (-1.79%) ▼|AMAT302.63-36.30 (-10.71%) ▼|AMD424.39-64.80 (-13.25%) ▼|AMGN435.64-0.66 (-0.15%) ▼|AMT184.21+3.06 (+1.69%) ▲|AMZN246.82-10.55 (-4.10%) ▼|AVGO304.41-42.24 (-12.19%) ▼|AXP301.70-9.41 (-3.02%) ▼|BA155.89-4.62 (-2.88%) ▼|BAC47.04-1.53 (-3.15%) ▼|BKNG144.91-2.41 (-1.64%) ▼|BLK1,101.72-34.09 (-3.00%) ▼|BMY58.80+0.46 (+0.79%) ▲|BNY141.24-3.59 (-2.48%) ▼|BRK-B570.00-2.04 (-0.36%) ▼|C110.62-4.66 (-4.04%) ▼|CAT510.45-26.92 (-5.01%) ▼|CL98.71+1.83 (+1.89%) ▲|CMCSA24.90+0.04 (+0.16%) ▲|COF178.66-3.10 (-1.71%) ▼|COP136.12+1.13 (+0.84%) ▲|COST1,102.15+8.32 (+0.76%) ▲|CRM180.62-2.69 (-1.47%) ▼|CSCO90.64-4.06 (-4.29%) ▼|CVS80.84+0.80 (+1.00%) ▲|CVX208.37+1.87 (+0.91%) ▲|DE609.25-15.64 (-2.50%) ▼|DHR220.36-7.20 (-3.16%) ▼|DIS117.98-2.27 (-1.89%) ▼|DUK129.78+0.92 (+0.71%) ▲|EMR150.93-6.67 (-4.23%) ▼|FDX303.99-10.65 (-3.38%) ▼|GD341.50-5.84 (-1.68%) ▼|GE309.62-9.26 (-2.90%) ▼|GEV699.33-56.95 (-7.53%) ▼|GILD166.43-0.10 (-0.06%) ▼|GM78.71-3.04 (-3.72%) ▼|GOOG264.00-7.02 (-2.59%) ▼|GOOGL265.29-7.37 (-2.70%) ▼|GS790.69-56.84 (-6.71%) ▼|HD339.04+2.36 (+0.70%) ▲|HON212.64-5.20 (-2.39%) ▼|IBM224.44+0.56 (+0.25%) ▲|INTC51.28-4.44 (-7.97%) ▼|INTU270.44-39.58 (-12.77%) ▼|ISRG399.05-8.19 (-2.01%) ▼|JNJ270.47+3.33 (+1.25%) ▲|JPM310.53-9.69 (-3.03%) ▼|KO96.99+0.90 (+0.94%) ▲|LIN502.83-7.38 (-1.45%) ▼|LLY1,347.11-4.01 (-0.30%) ▼|LMT565.50-6.35 (-1.11%) ▼|LOW220.84+1.70 (+0.78%) ▲|LRCX183.27-20.41 (-10.02%) ▼|MA625.59-0.91 (-0.15%) ▼|MCD273.24+0.89 (+0.33%) ▲|MDLZ66.28+0.59 (+0.90%) ▲|MDT99.94-0.67 (-0.67%) ▼|META560.84-35.38 (-5.93%) ▼|MMM177.99-0.48 (-0.27%) ▼|MO74.87+0.19 (+0.25%) ▲|MRK133.72+0.91 (+0.69%) ▲|MS165.67-9.31 (-5.32%) ▼|MSFT484.52-13.78 (-2.77%) ▼|MU594.51-95.93 (-13.89%) ▼|NEE83.45-0.34 (-0.41%) ▼|NFLX56.73-1.73 (-2.96%) ▼|NKE32.92-1.41 (-4.11%) ▼|NOW87.61-1.26 (-1.42%) ▼|NVDA125.53-20.45 (-14.01%) ▼|ORCL101.19-9.38 (-8.48%) ▼|PEP140.54+1.54 (+1.11%) ▲|PFE27.40-0.14 (-0.51%) ▼|PG169.37+1.52 (+0.91%) ▲|PLTR143.49-10.19 (-6.63%) ▼|PM184.09-2.34 (-1.26%) ▼|QCOM149.94-12.07 (-7.45%) ▼|RTX190.17-2.54 (-1.32%) ▼|SBUX103.13-1.34 (-1.28%) ▼|SCHW90.16-1.96 (-2.13%) ▼|SO93.13-0.16 (-0.17%) ▼|SPG224.35-0.87 (-0.39%) ▼|T22.31+0.46 (+2.11%) ▲|TMO669.54-19.21 (-2.79%) ▼|TMUS165.60+3.07 (+1.89%) ▲|TSLA345.82-28.59 (-7.64%) ▼|TXN263.75-22.00 (-7.70%) ▼|UBER63.47-2.13 (-3.25%) ▼|UNH339.85+9.37 (+2.84%) ▲|UNP287.29-3.34 (-1.15%) ▼|UPS106.22-2.89 (-2.65%) ▼|USB56.05-1.21 (-2.11%) ▼|V401.87-0.38 (-0.09%) ▼|VZ46.48+0.74 (+1.62%) ▲|WFC78.62-1.99 (-2.47%) ▼|WMT127.95+1.91 (+1.52%) ▲|XOM159.99+1.06 (+0.67%) ▲|
11.9 C
New York
Sunday, November 22, 2026

Tag: news

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Regencell (RGC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/23/2026

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Bronstein, Gewirtz & Grossman LLC Urges Calix, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Calix (CALX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/27/2026

Bronstein, Gewirtz & Grossman LLC Urges SES AI Corporation Investors to Act: Class Action Filed Alleging Investor Harm

New class action for SES AI (SES) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/26/2026

Bronstein, Gewirtz & Grossman LLC Urges Lucid Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Lucid (LCID) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/28/2026

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for GeneDx (WGS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 8/3/2026

Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph

Announced at FIRSTCON26, Modat brings Passive DNS to Magnify: one pivot from any signal to every related piece of attacker infrastructure
Announced at FIRSTCON26, Modat brings Passive DNS to Magnify: one pivot from any signal to every related piece of attacker infrastructure

Muscle Growth Supplements Featuring Magnesium, Ashwagandha and Omega-3s Are Highlighted by PureHealth Research

MANASSAS, Va., June 14, 2026 /PRNewswire/ -- Strength, mobility, and recovery are getting more attention from people who want to stay active for the...

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Orbis International’s Flying Eye Hospital Arrives in Peru to Expand Access to Essential Eye Care

With support from Alcon, FedEx, and OMEGA, the Orbis Flying Eye Hospital returns to Peru to carry out a training project in the city of Arequipa.AREQUIPA,...

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

SAMARITAN’S PURSE EBOLA TREATMENT CENTERS OPEN IN THE EPICENTER OF THE DEADLY OUTBREAK

BOONE, N.C., June 14, 2026 /PRNewswire/ -- Samaritan's Purse has established two Ebola Treatment Centers in Bunia and Nyankunde, Democratic Republic of Congo (DRC), to...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNews